# Lauxera Capital Partners

Lauxera Capital Partners is a Private Equity based in Paris, France.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Paris, France
- **Region:** Europe
- **Address:** Paris, France
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** lauxera.com
- **LinkedIn:** https://www.linkedin.com/company/lauxera-capital-partners

## Regulatory record

- **CRD number:** 313762
- **SEC file number:** 802-120884
- **Registration status:** ACTIVE
- **Latest Form ADV filing:** 2026-03-18T05:00:00.000Z
- **Reports private funds:** Yes
- **Private funds reported:** 0
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/313762

## About

We empower Healthtech entrepreneurs throughout their scale-up journey | Lauxera Capital Partners is an independent, international, investment fund focused on growth companies in Healthtech. Our growth equity investments focus primarily on commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- San Francisco, CA, United States

## People

- Pierre Moustial — Founding Partner
- Alexandre Margoline — Founding Partner

## Questions

### How does Lauxera source its deals?

The firm's sourcing model combines a European origination network built around clinical key opinion leaders with a transatlantic outbound channel through its San Francisco office. Lauxera's venture partner bench includes practicing surgeons and former FDA regulatory advisors, who surface companies within their clinical subspecialties before those companies engage traditional growth equity processes. This clinical-operator sourcing layer is central to its differentiation from generalist European growth funds.

### Does Lauxera participate in fund commitments or only direct deals?

Lauxera operates as a direct investor and does not allocate to external venture capital or growth equity funds. The firm's structure is a single-fund, deal-by-deal vehicle rather than a fund-of-funds or hybrid platform. Limited partners invest directly into Lauxera's growth fund, which then takes equity positions in individual portfolio companies.

### How is Lauxera's fund structured, and who are its anchor investors?

The firm launched its debut fund in 2020 with an anchor commitment from Bpifrance, the French sovereign wealth fund and public investment bank (per the firm's official communications). The fund operates as a closed-end vehicle with a standard 10-year life. Lauxera has not publicly disclosed its full LP base beyond Bpifrance, though the sovereign anchor aligns the firm with a long-duration capital partner that reinforces its regulatory-stage, patient-capital investment horizon.

### Which sectors does Lauxera explicitly avoid?

Lauxera does not invest in biopharma, drug discovery, or pre-clinical therapeutics. The firm also explicitly avoids digital health companies that lack a regulated-medical-device or diagnostic classification pathway — consumer wellness apps and general health SaaS fall outside its mandate. The exclusion of therapeutics and unregulated health software is central to its positioning as a commercial-stage medtech and diagnostics investor rather than a broad life sciences platform.

## Related profiles

- [Laureus Capital](https://altss.com/profile/laureus-capital)
- [LavBay Capital Management](https://altss.com/profile/lavbay-capital-management)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lauxera-capital-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology